Get the Stockscreener App
883.96
3.67%
-33.69
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $883.96, with a volume of 4.45M.
It is down -3.67% in the last 24 hours and down -2.11% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$917.65
Open:
$900.01
24h Volume:
4.45M
Relative Volume:
1.43
Market Cap:
$789.69B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
39.13
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-4.65%
1M Performance:
-2.11%
6M Performance:
+7.09%
1Y Performance:
+2.82%
1-Day Range:
$871.73
$900.42
1-Week Range:
$871.73
$930.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Ticino Wealth Makes New $1.31 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Optas LLC Has $4.18 Million Position in Eli Lilly and Company $LLY - MarketBeat
PFG Advisors Sells 3,261 Shares of Eli Lilly and Company $LLY - MarketBeat
$Eli Lilly and Co (LLY.US)$ Monday 917 and will keep up for few more days. - Moomoo
Why Eli Lilly Stock Flopped on Friday - Yahoo Finance
Why Eli Lilly Stock Flopped on Friday - The Motley Fool
Eli Lilly and Company (NYSE:LLY) Trading Down 3.6%Time to Sell? - MarketBeat
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly and Co (LLY) Stock Down 3.7% -- Now Undervalued? GF Sc - GuruFocus
Foundayo's Prescription Performance Raises Concerns for Eli Lill - GuruFocus
A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B - statnews.com
Lilly's obesity pill records modest second week as battle with Novo intensifies - Reuters
Eli Lilly shares see Morgan Stanley commentary on Mounjaro, Zepbound scripts - Investing.com Canada
Lilly’s CAR-T devotion; CBER’s next top dog? - Pharma Voice
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow - TechStock²
LLY Stock Slides Toward Sixth Weekly Loss, But 200-DMA Holds Firm: Is It Setting Up For Earnings Run? - Stocktwits
Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims - Yahoo Finance
Eli Lilly slides as weekly GLP-1 prescription data raises near-term demand questions - Quiver Quantitative
Eli Lilly and Co Stock (LLY) Moved Down by 3.03% on Apr 24: What Investors Need To Know - TradingKey
Eli Lilly Shares Dip Despite Stable Growth in GLP-1 Prescriptions - Yahoo Finance
Eli Lilly (LLY) Faces Pressure as Weight Loss Drug Prescriptions Lag Behind Competitor - GuruFocus
Lilly’s New Obesity Pill Off to Slow Start in Race With Novo - Yahoo Finance
LLY stock clings to 200-DMA as sell-off deepens: Retail eyes 'positioning' play ahead of Q1 earnings next week - MSN
Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy - Seeking Alpha
Eli Lilly stock slips despite steady GLP-1 script growth By Investing.com - Investing.com UK
Eli Lilly stock slips despite steady GLP-1 script growth - Investing.com
Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Drug company Lilly refuses to list Mounjaro on PBS, says price too low - AFR
Eli Lilly (LLY) Expands Partnership with Hims & Hers - TipRanks
Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership - GuruFocus
BofA raises Hims and Hers stock price target on Lilly partnership - Investing.com
Hims & Hers jumps 7% after expanding partnership with Eli Lilly - Yahoo Finance
Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days - Stocktwits
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q1 Earnings - TradingView
Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
AI Models Split on Eli Lilly (LLY) as Growth Strengths Collide With Valuation Risks - TipRanks
Lilly Q1 2026 earnings conference call - Moomoo
3 Healthcare Stocks With the Most Durable Competitive Moats - AOL.com
Eli Lilly Case Over Weight Loss Drugs Kept Mostly Intact - Law360
Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects - Insider Monkey
Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. - The Motley Fool
Bernstein Pounds the Table on Eli Lilly Stock (LLY) Ahead of Q1 Earnings - TipRanks
Parkland School Board members concerned a tax break for Eli Lilly would shortchange district - The Morning Call
Weight Loss Drug Market Resilience Amid Medicare Challenges - GuruFocus
Lilly’s Suit Against Mounjaro Copies Advances in Second Attempt - Bloomberg Law News
Eli Lilly shares trade sideways as Foundayo launches with strong initial prescriptions: weekly report - Traders Union
Medicare delays GLP-1 coverage plan; interim program extended - Seeking Alpha
Here is why Eli Lilly (LLY) is Among the 8 Best Beginner Stocks to Buy Right Now - Insider Monkey
LLY Stock Price, Quote & Chart | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly Stock (LLY) Opinions on Amazon's GLP-1 Program Launch - Moomoo
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):